These agreements are the 13th, 14th, and 15th contracts or extensions to date in 2023 vs 28 in all of 2022
News in Summary
KITCHENER, ON / ACCESSWIRE / March 27, 2023 / Cloud DX (TSXV:CDX) (OTC:CDXFF),a leading health data platform, announces a new US contract and two Canadian contract extensions, bringing this year's total agreements to date to 15, compared to 28 in all of 2022.
Cloud DX welcomes an Illinois based primary care clinic as its next US clinic to implement an RPM program. The concierge clinic will offer Connected Health™ to improve outcomes and service for its existing clients and to attract a new client base. The practice, serving over 365 patients primarily seniors, estimates 50% will enroll in its Connected Health™ RPM program to manage chronic conditions including CHF, COPD, hypertension, and diabetes. The estimated value of the deployment is up to $170,000 CAD in the first full year.
Cloud DX also signed extension contracts with two Ontario based health providers. After a successful initial deployment, an Ontario Family Health Team is extending its RPM contract for an additional 6 months to provide Connected Health™ services to palliative care patients. An Ontario Community Paramedic program for chronic care management is extending its Cloud DX RPM contract for another 12 months, with the potential to double the number of patients currently using Connected Health kits and services. Contract value for these deployment extensions is estimated to be up to $90,000 CAD over 12 months.
These additional agreements follow Cloud DX's earlier announcement of the expansion of 5 existing Remote Patient Monitoring contracts, a 150% increase in YoY growth in contract extensions.
Founder and CEO Robert Kaul stated "We continue to see demand for virtual care and remote monitoring increase in North America as healthcare providers seek to leverage our proven Connected Health technologies to improve care delivery, patient satisfaction, and reduce costs. Cloud DX is excited to see growth in the number of new contracts signed so far in 2023 as well as a significant number of contract extensions, which indicate that we are doing a good job making healthcare better for all our stakeholders."
ABOUT CLOUD DX
Cloud DX is on a mission to make healthcare better for everyone. Clinics and hospitals across North America use our Connected Health™ data platform to incorporate remote and virtual technology in care delivery. Our remote monitoring solutions let care teams virtually monitor hundreds of patients; Patients take vital signs at home with intelligent medical devices which transmit the data to the care team's dashboard or EMR. Connected Health™ supports remote vital sign monitoring, behavioral medicine, telehealth, care pathways for chronic care, aging in place, palliative or perioperative hospital-at-home, and more. Our customers achieve better healthcare and patient outcomes, reduce hospitalizations and readmissions, lower care delivery costs, and grow patient panels, revenue, and more.
Cloud DX is an exclusive partner to Medtronic Canada, Teladoc Health Canada, and Equitable Life of Canada. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, 2022 Top Innovator by Canadian Business, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers."
For more information on Cloud DX (TSXV:CDX), visit www.CloudDX.com and follow @CloudDX on Twitter or LinkedIn.
Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Media Contact
Janine Scott
Marketing Lead
888-543-0944
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contacts
Canada
Jay Bedard
647-881-8418
This email address is being protected from spambots. You need JavaScript enabled to view it.
USA
Gary Zwetchkenbaum
516-455-7662
This email address is being protected from spambots. You need JavaScript enabled to view it.
Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect ", "is expected ", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. In particular, this news release includes certain forward-looking statements concerning the advancement of the Company's business and partnerships, the expected proceeds therefrom, regulatory approvals, as well as management's objectives, strategies, beliefs, and intentions.
Last Trade: | C$0.13 |
Daily Volume: | 0 |
Market Cap: | C$11.640M |
April 29, 2024 April 23, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB